Key result
Streptokinase resulted in a 1-year mortality rate of 7.4% compared to 0% with tenecteplase in patients with STEMI treated at a rural peripheral hospital.
Why the study?
This study determined 1-year mortality in patients receiving rapid thrombolysis with streptokinase or tenecteplase at a rural primary care hospital.
Does thrombolysis with tenecteplase compared to streptokinase improve 1-year mortality in patients with STEMI at a rural peripheral hospital?
Cohort (n=209)
No
Does thrombolysis with tenecteplase compared to streptokinase improve 1-year mortality in patients with STEMI at a rural peripheral hospital?
In a rural hospital setting, early thrombolysis for STEMI is feasible and improves reperfusion, with tenecteplase showing a trend toward lower 1-year mortality compared to streptokinase.
Answers are grounded in this paper and cite their sources.
Should not yet change thrombolytic choice in rural STEMI; leaves open comparative effectiveness of tenecteplase versus streptokinase.
BACKGROUND: Coronary artery disease is a major cause of death in India. Sudden death preceded by chest pain is due to acute myocardial infarction. Villagers are aware and afraid of chest pain. Majority of chest pain victims attend the primary physician in golden hours. Hence, primary doctors can play important role for early thrombolysis and salvage the myocardium from irreversible injury. This study determined year mortality in a patient who received the rapid thrombolysis at primary care hospital (streptokinase or tenecteplase) at rural setting. SETTING: Peripheral General Hospital Mahad on Mumbai-Goa highway. PATIENTS AND METHODS: Patients with typical chest pain with electrocardiogram showed ST segment elevated myocardial infarction (STEMI) with or without risk factors admitted from 2005 to march 2016 were studied. Details clinically studied: time interval between chest pain to hospital, hospital to needle time, reperfusion and arrhythmias. Time required for regression of elevated ST segment, a response to thrombolytic (streptokinase or tenecteplase) therapy, is studied. CONCLUSION: Thrombolysis of STEMI within golden hours improved the reperfusion. However, 1-year fatality is significance with streptokinase as compared with tenecteplase.
No takes yet. Share an insight, caveat, or question.
Bawaskar et al. (2019) conducted a cohort in ST segment elevation myocardial infarction (STEMI) (n=209). Streptokinase vs. Tenecteplase was evaluated on 1-year mortality (p=0.072). Streptokinase resulted in a 1-year mortality rate of 7.4% compared to 0% with tenecteplase in patients with STEMI treated at a rural peripheral hospital.
Synapse has enriched 10 related papers. Consider them for comparative context: